CoChat

Solubility based mechanistic profiling of combinatorial drug therapy

Gholizadeh, Elham, Zangene, Ehsan, Vadadokhau, Uladzislau, Ritz, Danilo, Miettinen, Juho J., Soliymani, Rabah, Baumann, Marc, Wilhelm, Mathias, Kankuri, Esko, Haynes, Paul A., Heckman, Caroline A., Saei, Amir A., Jafari, Mohieddin · 2026 · Nature Communications

Published version of a preprint

Cited by 5

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-026-70394-3

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 67

  1. Döhner, K., Paschka, P. & Döhner, H. [Acute myeloid leukemia]. Internist 56, 354–363 (2015). · DOI
  2. Cherry, E. M. et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 5, 5565–5573 (2021). · DOI · Paper page
  3. Karol, S. E. et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 21, 551–560 (2020). · DOI · Paper page
  4. Mason-Osann, E., Pomeroy, A. E., Palmer, A. C. & Mettetal, J. T. Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood Cancer Discov. 5, 95–105 (2024). · DOI
  5. Tyner, J. et al. Functional genomic landscape of acute myeloid leukemia. Nature 562, 526–531 (2018). · DOI · Paper page
  6. Tang, K., Schuh, A. C. & Yee, K. W. 3+7 Combined chemotherapy for acute myeloid leukemia:is it time to say goodbye? Curr. Oncol. Rep. 23, 120 (2021). · DOI
  7. Wang, J., Tomlinson, B. & Lazarus, H. M. Update on small molecule targeted therapies for acute myeloid leukemia. Curr. Treat. Options Oncol. 24, 770–801 (2023). · DOI
  8. Mirzaie, M. et al. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling. Oncogenesis 13, 11 (2024). · DOI · Paper page
  9. Gholizadeh, E. et al. Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations. Biomed. Pharmacother. 192, 118647 (2025). · DOI
  10. Mateus, A., Määttä, T. A. & Savitski, M. M. Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes. Proteome Sci. 15, 13 (2016). · DOI · Paper page
  11. Saei, A. A. et al. Multifaceted proteome analysis at solubility, redox, and expression dimensions for target identification. Adv. Sci. 11, e2401502 (2024). · DOI
  12. Van Vranken, J. G. et al. Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays. eLife 13, RP95595 (2024). · DOI
  13. Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567–1593 (2015). · DOI · Paper page
  14. Jafari, M., Ansari-Pour, N., Azimzadeh, S. & Mirzaie, M. A logic-based dynamic modeling approach to explicate the evolution of the central dogma of molecular biology. PLoS ONE 12, e0189922 (2017). · DOI
  15. Tian, C. et al. UCHL1 promotes cancer stemness in triple-negative breast cancer. Pathol. Res. Pract. 240, 154235 (2022). · DOI
  16. Meng, Y. et al. Research advances in the role of the tropomyosin family in cancer. Int. J. Mol. Sci. 24, 13295 (2023). · DOI
  17. Estecha, A., Aguilera-Montilla, N., Sánchez-Mateos, P. & Puig-Kröger, A. RUNX3 regulates intercellular adhesion molecule 3 (ICAM−3) expression during macrophage differentiation and monocyte extravasation. PLoS ONE 7, e33313 (2012). · DOI
  18. Greuber, E. K., Smith-Pearson, P., Wang, J. & Pendergast, A. M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13, 559–571 (2013). · DOI · Paper page
  19. Carter, J. L. et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct. Target. Ther. 5, 288 (2020). · DOI · Paper page
  20. Bottani, E. et al. TTC19 plays a husbandry role on UQCRFS1 turnover in the biogenesis of mitochondrial respiratory complex III. Mol. Cell 67, 96–105 (2017). · DOI
  21. Borkar, R. M. et al. An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. Biomed. Chromatogr. 30, 1556–1572 (2016). · DOI
  22. Müller, S., Ledl, A. & Schmidt, D. SUMO: a regulator of gene expression and genome integrity. Oncogene 23, 1998–2008 (2004). · DOI · Paper page
  23. Ghelli Luserna di Rorà, A., Martinelli, G. & Simonetti, G. The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window? J. Hematol. Oncol. 12, 123 (2019). · DOI
  24. Cheng, Y. et al. Tumor microenvironmental competitive endogenous RNA network and immune cells act as robust prognostic predictor of acute myeloid leukemia. Front. Oncol. 11, 584884 (2021). · DOI
  25. Trombetti, S. et al. Oxidative stress and ROS-mediated signaling in leukemia: Novel promising perspectives to eradicate chemoresistant cells in myeloid leukemia. Int. J. Mol. Sci. 22, 2470 (2021). · DOI
  26. Addanki, S., Kim, L. E. & Stevens, A. M. Understanding and targeting metabolic vulnerabilities in acute myeloid leukemia: An updated comprehensive review. Cancers17, (2025). · DOI
  27. Saraon, P. et al. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene 40, 4079–4093 (2021). · DOI · Paper page
  28. Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36, 13–22 (2021). · DOI · Paper page
  29. Pabst, T. & Mueller, B. Transcriptional dysregulation during myeloid transformation in AML. Oncogene 26, 6829–6837 (2007). · DOI
  30. Biffo, S., Ruggero, D. & Santoro, M. M. The crosstalk between metabolism and translation. Cell Metab. 36, 1945–1962 (2024). · DOI
  31. Crews, L. A. et al. RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML. Cell Stem Cell 19, 599–612 (2016). · DOI · Paper page
  32. Chen, C. & Zhang, J. Enhancing leukemia treatment: The role of combined therapies based on amino acid starvation. Cancers16, 1171 (2024). · DOI
  33. Ciciarello, M., Corradi, G., Forte, D., Cavo, M. & Curti, A. Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: Tangle or chance? Cancers13, 5319 (2021). · DOI
  34. Teague, R. M. & Kline, J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J. Immunother. Cancer 1, 13 (2013). · DOI
  35. Fan, C., Yang, X., Yan, L. & Shi, Z. Oxidative stress is two-sided in the treatment of acute myeloid leukemia. Cancer Med. 13, e6806 (2024). · DOI
  36. Yates, L. A., Zhang, X. & Burgers, P. M. DNA damage and replication stress checkpoints. Annu. Rev. Biochem. 94, 195–221 (2025). · DOI
  37. Weisberg, E. et al. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34, 625–629 (2020). · DOI
  38. Nickchi, P. et al. Monitoring functional posttranslational modifications using a data-driven proteome informatic pipeline. Proteomics 25, e202400238 (2025). · DOI
  39. Liu, X. et al. Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc. Natl. Acad. Sci. USA 104, 9679–9684 (2007). · DOI
  40. Shandilya, J. et al. Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancer manifestation. Mol. Cell. Biol. 29, 5115–5127 (2009). · DOI
  41. Langland, G. et al. The BLM helicase is necessary for normal DNA double-strand break repair. Cancer Res. 62, 2766–2770 (2002).
  42. Wang, Y. & Luo, J. Acetylation of BLM protein regulates its function in response to DNA damage. RSC Adv. 7, 55301–55308 (2017). · DOI
  43. Ouyang, K. J., Yagle, M. K., Matunis, M. J. & Ellis, N. A. BLM SUMOylation regulates ssDNA accumulation at stalled replication forks. Front. Genet. 4, 167 (2013). · DOI
  44. Pomeroy, A. E., Schmidt, E. V., Sorger, P. K. & Palmer, A. C. Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer Res. 8, 915–929 (2022). · DOI · Paper page
  45. Arnone, M. et al. Acute myeloid leukemia stem cells: The challenges of phenotypic heterogeneity. Cancers12, 3742 (2020). · DOI
  46. Filì, C. et al. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. Leuk. Res. 76, 33–38 (2019). · DOI
  47. Palma, A. et al. Integrating patient-specific information into logic models of complex diseases: Application to acute myeloid leukemia. J. Pers. Med. 11, 117 (2021). · DOI
  48. Price, J. L. et al. Context-dependent effects of asparagine glycosylation on Pin WW folding kinetics and thermodynamics. J. Am. Chem. Soc. 132, 15359–15367 (2010). · DOI
  49. Jayavelu, A. K. et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40, 301–317 (2022). · DOI
  50. Bliss, C. I. The toxicity of poisons applied jointly1. Ann. Appl. Biol. 26, 585–615 (1939). · DOI · Paper page
  51. de Oliveira Lisboa, M., Brofman, P., Schmid-Braz, A. T., Rangel-Pozzo, A. & Mai, S. Chromosomal instability in acute myeloid leukemia. Cancers13, 2655 (2021). · DOI
  52. Guan, L. et al. Regulation of the tumor immune microenvironment by cancer-derived circular RNAs. Cell Death Dis. 14, 132 (2023). · DOI
  53. Chen, Y., Chen, J., Zou, Z., Xu, L. & Li, J. Crosstalk between autophagy and metabolism: implications for cell survival in acute myeloid leukemia. Cell Death Discov. 10, 46 (2024). · DOI
  54. Wallwitz, J., Aigner, P. & Stoiber, D. Tumor suppressors in acute myeloid leukemia. Leuk. Lymphoma 62, 2320–2330 (2021). · DOI
  55. Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010). · DOI · Paper page
  56. Woods, B. A. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Immunol. Rev. 263, 22–35 (2015). · DOI · Paper page
  57. Falini, B., Sportoletti, P. & Martelli, M. P. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr. Opin. Oncol. 21, 573–581 (2009). · DOI
  58. Barbosa, K., Li, S., Adams, P. D. & Deshpande, A. J. The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes Cancer 58, 875–888 (2019). · DOI
  59. Cuartero, S., Innes, A. J. & Merkenschlager, M. Towards a better understanding of cohesin mutations in AML. Front. Oncol. 9, 867 (2019). · DOI
  60. Steelman, L. S. et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 25, 1080–1094 (2011). · DOI · Paper page
  61. Leuchtmann, A. B., Afifi, Y., Ritz, D. & Handschin, C. Effects of high-resistance wheel running on hallmarks of endurance and resistance training adaptations in mice. Physiol. Rep. 11, e15701 (2023). · DOI
  62. Saei, A. A. et al. Mapping the GALNT1 substrate landscape with versatile proteomics tools. https://doi.org/10.1101/2022.08.24.505189. (2022) · DOI
  63. Saei, A. A. et al. System-wide identification and prioritization of enzyme substrates by thermal analysis. Nat. Commun. 12, 1296 (2021). · DOI
  64. Sabatier, P. et al. An integrative proteomics method identifies a regulator of translation during stem cell maintenance and differentiation. Nat. Commun. 12, 6558 (2021). · DOI
  65. Deutsch, E. W. et al. The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res. 51, D1539–D1548 (2023). · DOI · Paper page
  66. Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543–D553 (2025). · DOI · Paper page
  67. Perez-Riverol, Y. et al. PRIDE Inspector toolsuite: moving toward a universal visualization tool for proteomics data standard formats and quality assessment of poteomeXchange datasets. Mol. Cell Proteom. 15, 305–317 (2016). · DOI · Paper page

Cited by

See all 5

Metadata

Authors
Gholizadeh, E., Zangene, E., Vadadokhau, U., Ritz, D., Miettinen, J. J., Soliymani, R., Baumann, M., Wilhelm, M., Kankuri, E., Haynes, P. A., Heckman, C. A., Saei, A. A., & Jafari, M.
Venue
Nature Communications
Published
2026-03-25
Volume
17
Issue
1
ISSN
2041-1723
Cited by
5
References
9
Language
en
Licence
Funders
  • Academy of Finland (332454)
  • Jane ja Aatos Erkon Säätiö (220031)
  • Sigrid Juséliuksen Säätiö
  • Syöpäsäätiö (4709178)
  • Cancerfonden (243595 Pj)
  • Vetenskapsrådet (2023-02692)
  • Jeanssons Stiftelser (J2023-0094)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Solubility based mechanistic profiling of combinatorial drug therapy. https://app.cochat.ai/papers/10.1038/s41467-026-70394-3
The paper
Gholizadeh, E., Zangene, E., Vadadokhau, U., Ritz, D., Miettinen, J. J., Soliymani, R., Baumann, M., Wilhelm, M., Kankuri, E., Haynes, P. A., Heckman, C. A., Saei, A. A., & Jafari, M. (2026). Solubility based mechanistic profiling of combinatorial drug therapy. Nature Communications. https://doi.org/10.1038/s41467-026-70394-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.